Catalent, Acticor Biotech Partner
By

Acticor Biotech, a biopharmaceutical company, has selected Catalent's proprietary GPEx technology for the development of its Fab candidate, ACT-017, targeting the platelet glycoprotein VI (GPVI).

The GPEx platform creates mammalian cell lines for early feasibility studies, to clinical manufacturing, through to commercial-scale production. To date, seven GPEx based antibody and protein products are approved and marketed, and 34 therapeutic candidates are currently undergoing clinical trials using the platform.

Acticor Biotech is an Inserm spin-off. Founded in late 2013, the company's is primarily focused on developing the anti-GPVI antibody as a platelet-aggregation inhibitor for acute thrombotic pathologies.

Source: Catalent

Leave a Reply

Your email address will not be published. Required fields are marked *